Both AHR and CTRE operate in the healthcare real estate sector, yet they pursue meaningfully different growth models. This stock comparison is relevant for investors evaluating how two fast-growing healthcare REITs are positioned amid shifting interest rates, an aging population, and active acquisition pipelines. One is a senior-housing operator capturing upside directly, while the other is a net-lease landlord diversifying internationally. Understanding their relative performance, capital structures, and momentum helps traders and longer-term investors weigh market positioning — and assess which name currently presents the stronger risk-adjusted setup. I also checked this using Tickeron’s AI Screener to see how the stocks compare to others in the industry.
American Healthcare REIT (AHR) owns and operates a diversified healthcare portfolio spanning senior housing operating properties (SHOP), integrated senior health campuses under its Trilogy platform, outpatient medical buildings, and triple-net leased assets. Its operating model is the centerpiece of the story, allowing the company to capture revenue and margin upside directly rather than relying solely on fixed rents.
Recent market activity has been notably supportive. The company reported third-quarter normalized funds from operations (NFFO) of $0.58 per share, beating consensus, and extended its streak of double-digit same-store NOI growth to 11 straight quarters. SHOP same-store NOI growth accelerated to 28.2%, while total portfolio NOI grew 13.8%. Management raised full-year NFFO guidance to a range of $2.23–$2.26, its third increase of the year, and reduced net debt-to-EBITDA to about 1.9x. The shares have outperformed the broader market this year, and analyst consensus remains a "Strong Buy" with an average price target well above recent trading levels. That said, meaningful share issuance to fund roughly $2 billion in completed investments introduces some dilution that investors are weighing against accelerating per-share growth. From what I see, the consistent organic growth here stands out.
CareTrust REIT (CTRE) is a self-administered REIT that owns, acquires, and leases skilled nursing, seniors housing, and other healthcare properties, primarily through long-term triple-net leases. It has historically maintained low leverage and a strong balance sheet, which has supported an aggressive acquisition program.
Fundamentally, the company has delivered accelerating results. Third-quarter normalized FFO reached $0.54 per share, up 20% year over year, and management raised full-year guidance for the fourth time. Year-to-date investments have climbed to roughly $2.9 billion, headlined by a partnership to acquire 45 newly built U.K. care homes. Despite this, the stock has experienced a notable pullback in recent weeks, trading below its 200-day moving average as investors weighed lower blended deal yields, rising leverage, and a series of equity offerings — including a roughly $637.5 million common stock offering priced this month. The dividend yield near 4% and a "Buy" consensus provide a measure of support, but near-term sentiment has cooled relative to the company's operating momentum.
The clearest contrast between the two names lies in their business models. AHR derives much of its growth from operating senior housing, capturing margin expansion directly as occupancy and pricing improve. CTRE, by comparison, is predominantly a triple-net landlord whose tenants bear operating risk, while the company expands its asset base through acquisitions and a new U.K. foothold.
Growth drivers also differ. AHR's momentum is anchored in same-store NOI acceleration and disciplined pricing, with an acquisition pipeline exceeding $1 billion. CTRE's growth is more external, driven by a record investment pace, though blended yields have edged lower and leverage has crept upward. On market sentiment, AHR has enjoyed favorable price action and estimate revisions, while CTRE faces a disconnect between strong earnings and negative price reaction tied to dilution concerns. Risk factors for AHR include operator execution and share issuance; for CTRE, they center on integration of the U.K. platform and financing-related overhang. One thing that stands out is how these differences shape near-term positioning.
Based on observable trend consistency, relative strength, and market positioning, Tickeron's AI would currently favor AHR. The stock has sustained a steadier uptrend, delivered repeated upward guidance revisions supported by organic same-store growth, and maintained a stronger analyst consensus with meaningful upside to average price targets. While CTRE shows impressive fundamental acceleration, its recent price action and financing-related sentiment shift suggest less favorable short-term positioning. These conditions give AHR a probabilistic edge at present, though the balance could shift as either company's catalysts and capital markets evolve.
In my analysis of these two REITs, I turned to Tickeron’s AI Daily Buy/Sell Signals to cross-check momentum signals across the sector. It offers a quick way to see how automated models are interpreting recent price and volume data alongside the fundamental trends we’ve discussed. This step helped confirm the relative strength I was observing without adding extra layers of complexity to the review.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
The 10-day moving average for CTRE crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 73%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on CTRE as a result. In 48 of 80 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
CTRE moved above its 50-day moving average on November 04, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.52% 3-day Advance, the price is estimated to grow further. Considering data from situations where CTRE advanced for three days, in 217 of 324 cases, the price rose further within the following month. The odds of a continued upward trend are 67%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 26 of 64 cases where CTRE's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 41%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CTRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 49%.
CTRE broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CTRE entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating fairly steady price growth. CTRE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.010) is normal, around the industry mean (3.134). P/E Ratio (23.881) is within average values for comparable stocks, (30.791). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (1.649). Dividend Yield (0.041) settles around the average of (0.050) among similar stocks. CTRE's P/S Ratio (18.762) is very high in comparison to the industry average of (6.013).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a real estate investment trust
Industry PublishingBooksMagazines